EnGeneIC performs research, development and manufacturing of targeted anti-cancer therapies.
Abstract Demonstrates Promising Early Results from Phase I/IIa study in Patients with Recurrent, Metastatic Pancreatic Cancer.
EDV™ Technology Stimulates Both Innate and
Adaptive Immune Response and Confers Long-Term Survival
The 10 Most Innovative Healthcare Nanotech Companies to Watch
Named Most Innovative Healthcare Company of 2019 for its Nanocell Platform for Targeted Cyto-Immunotherapy in Cancer Treatment